Chapter 8: Carbohydrates and Glycomimetics in Alzheimer's Disease Therapeutics and Diagnosis
-
Published:30 Mar 2015
-
Special Collection: 2015 ebook collection , 2011-2015 industrial and pharmaceutical chemistry subject collectionSeries: Drug Discovery Series
C. Dias and A. P. Rauter, in Carbohydrates in Drug Design and Discovery, ed. J. Jimenez-Barbero, F. J. Canada, and S. Martin-Santamaria, The Royal Society of Chemistry, 2015, ch. 8, pp. 180-208.
Download citation file:
Alzheimer's disease is the most prevalent form of late-life dementia, affecting millions worldwide. The devastating nature of the disease, unsuccessful treatment options and high socio-economic impact has inspired scientists to develop new structures with neuroprotective properties. Although currently available drugs target cholinergic neurotransmission, investigation towards disease-modifying therapies has been growing and carbohydrates have been playing an active role in the latest discoveries. Sugars, as polyfunctional compounds particularly important in biology and widely involved in human health and disease, have great potential to generate bioactive and bioavailable interesting molecules. Herein we discuss the importance of carbohydrates and glycomimetic structures, addressing different aspects of neuroprotection under investigation, targeting amyloid, tau and cholinergic hypotheses. The potential of carbohydrates in diagnosis is also discussed.